A new early-stage clinical trial found that a novel monoclonal antibody provided dose-dependent full protection against the ...

Gyre Pharmaceuticals has completed participant enrolment for its 52-week Phase III clinical trial assessing Pirfenidone ...

Malaria remains one of the leading causes of death among children in sub-Saharan Africa, claiming more than 600,000 lives ...

Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient MeetingEnrollment underway for ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

A Dutch study involving more than 1100 men found that the antioxidant supplement Impryl did not improve fertility. The trial, ...

The study was led by Dr. Jia Sun from the Department of Endocrinology, Zhujiang Hospital of Southern Medical University, ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ...

Rivus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to treating obesity and the resulting ...

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...

Baxdrostat, a novel aldosterone synthase inhibitor, demonstrated a highly clinically meaningful reduction in 24-hour ...